1.
Transpl Infect Dis
; 25(3): e14025, 2023 06.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36715644
2.
Liver Transpl
; 28(2): 314-316, 2022 02.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34416086
3.
Minerva Anestesiol
; 88(3): 199-201, 2022 03.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34636225
4.
Transpl Int
; 34(10): 1984-1986, 2021 10.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34148258
5.
Transpl Infect Dis
; 22(5): e13334, 2020 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32449235
RESUMEN
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.